Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability

George Alexander Jelinek, Tracey J Weiland, Emily Hadgkiss, Claudia H Marck, Naresh G Pereira, Dania M van der Meer

Research output: Contribution to journalArticleResearchpeer-review

24 Citations (Scopus)


Objectives: To examine associations between medication use and health-related quality of life (HRQOL), relapse rate and disability in an international cohort of people with multiple sclerosis (PwMS). Methods: Using Web 2.0 platforms, the authors recruited PwMS who completed survey items on demographics, medication use, HRQOL, relapse rate and disability. Results: Of respondents from 56 countries, approximately half were taking a disease-modifying drug (DMD), most commonly glatiramer acetate or an interferon. Use of DMDs was not consistently associated with HRQOL. Individually, glatiramer acetate was associated with better HRQOL when compared with other DMDs or no DMD use. Overall, DMD use was neither associated with disability nor lower relapse rate, although those taking a DMD
Original languageEnglish
Pages (from-to)662 - 673
Number of pages12
JournalNeurological Research
Issue number8
Publication statusPublished - 2015

Cite this